Basma Adeem Medical Co. (9626.SR) — Cash flow
Operating, investing, and financing cash flow for Basma Adeem Medical Co. — annual and quarterly.
| Metric (SAR Millions) | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | 6↑29.4% | 5↑28.7% | 4 | |
| Depreciation & Amortization | 1↑7.3% | 1↑50.8% | 0.77 | |
| Deferred Income Tax | 0.00 | 0.00 | 0.00 | |
| Stock-Based Compensation | 0.00 | 0.00 | 0.00 | |
| Changes in Working Capital | -0.37↑72.5% | -1↓162.9% | 2 | |
| Accounts Receivable | -0.07↑84.3% | -0.46↓474.7% | -0.08 | |
| Inventory | -0.59↓25.6% | -0.47↓281.3% | -0.12 | |
| Accounts Payable | -0.09↑75.5% | -0.36↓114.8% | 2 | |
| Other Working Capital | 0.38↑727.0% | -0.06↓7.7% | -0.06 | |
| Other Non-Cash Items | 0.80↑52.5% | 0.52↑56.0% | 0.33 | |
| Net Cash from Operating Activities | 8↑53.2% | 5↓26.0% | 7 | |
| Operating Cash Flow | 8↑56.7% | 5↓27.7% | 7 | |
| Investing Activities | ||||
| Investment in Property, Plant & Equipment | -1↓29.1% | -1↑43.3% | -2 | |
| Capital Expenditure | -1↓29.1% | -1↑43.3% | -2 | |
| Acquisitions | 0.00 | 0.00 | 0.00 | |
| Purchases of Investments | 0.00 | 0.00 | 0.00 | |
| Sales & Maturities of Investments | 0.00 | 0.00 | 0.00 | |
| Other Investing Activities | 0.00↑100.0% | -0.12 | 0.00 | |
| Net Cash from Investing Activities | -1↓15.6% | -1↑36.7% | -2 | |
| Financing Activities | ||||
| Net Debt Issuance | 0.00 | 0.00 | 0.00 | |
| Long-Term Net Debt Issuance | 0.00 | 0.00 | 0.00 | |
| Short-Term Net Debt Issuance | 0.00 | 0.00 | 0.00 | |
| Net Stock Issuance | 7 | 0.00 | 0.00 | |
| Net Common Stock Issuance | 7 | 0.00 | 0.00 | |
| Common Stock Issuance | 7 | 0.00 | 0.00 | |
| Share Buybacks | 0.00 | 0.00 | 0.00 | |
| Net Preferred Stock Issuance | 0.00 | 0.00 | 0.00 | |
| Dividends Paid | 0.00 | 0.00↑100.0% | -4 | |
| Common Dividends Paid | 0.00 | 0.00↑100.0% | -4 | |
| Preferred Dividends Paid | 0.00 | 0.00 | 0.00 | |
| Other Financing Activities | -1↓11.3% | -1↓76.4% | -0.63 | |
| Net Cash from Financing Activities | 5↑575.4% | -1↑73.8% | -4 | |
| Cash Reconciliation | ||||
| Effect of Foreign Exchange | 0.00 | 0.00↓100.0% | 4 | |
| Net Change in Cash | 12↑302.8% | 3↓42.6% | 5 | |
| Cash at Beginning of Period | 8↑57.4% | 5 | 0.00 | |
| Cash at End of Period | 20↑146.9% | 8↑57.4% | 5 | |
| Income Taxes Paid | 0.00 | 0.00 | 0.00 | |
| Interest Paid | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | 7↑63.7% | 4↓22.3% | 5 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.